Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era
PET-adapted treatment strategies improve outcomes in patients with advanced‑stage classical Hodgkin lymphoma while reducing treatment‑related toxicity.
This review summarizes randomized and phase‑II trials that evaluate PET‑guided de‑escalation and escalation in advanced‑stage classical Hodgkin lymphoma (AS‑cHL). It highlights that early PET negativity allows safe reduction of chemotherapy intensity and that PET positivity guides intensification with BEACOPP or ASCT. The evidence supports PET‑adapted algorithms that maintain high progression‑free survival (>85 %) while lowering cumulative toxicity.
PET‑adapted strategies enable personalization of therapy, preventing overtreatment and long‑term sequelae in otherwise curable disease.
Bizonyítékszint: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Kapcsolódó jelek
- Advanced Classical Hodgkin Lymphoma Management in East and Southeast Asia: Real-World Challenges and Aspirations of the Asian Lymphoma Study Group.
- Overcoming PD‑1 Resistance in Relapsed/Refractory Hodgkin Lymphoma
- Combination of Acimtamig and AlloNK Effective in R/R Classical Hodgkin Lymphoma
- Working towards harmonization of clinical trial reporting in Hodgkin lymphoma
- Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies